Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma.

ABSTRACT: Immune checkpoint inhibitors have been approved as second-line therapy for patients with advanced urothelial carcinoma (UC). However, which patients will obtain clinical benefit remains to be determined. To identify predictive biomarkers for the pembrolizumab (PEM) response early during treatment, the present study investigated 31 patients with chemotherapy-resistant recurrent or metastatic UC who received 200 mg PEM intravenously every 3 weeks. Blood was taken just before the first dose and again before the second dose, and the peripheral blood mononuclear cells of all 31 pairs of blood samples were immune phenotyped by flow cytometry. Data were assessed by principal component analysis (PCA), correlation analysis and Cox proportional hazards modeling in order to comprehensively determine

SUBMITTER: Teshima T 

PROVIDER: S-EPMC9219027 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature